Japan-based CRO joins Align Clinical Group to aid global clinical trial execution

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/metamorworks)
(Image: Getty/metamorworks)

Related tags: CRO, Clinical research, Clinical trial, Align Clinical CRO, Globalization, Japan

CMIC Group is the first Japanese CRO to join the Align Clinical group and expects to improve execution of clinical trials and collaboration with life sciences companies as the industry grows globally.

The Japan-based contract research organization (CRO), CMIC Group, joined the life sciences industry standards​ group Align Clinical CRO​, as the first member from Japan.

According to Keiko Oishi, president and COO of CMIC, “The global health care industry is going through a significant change. The types of service request and qualification requirements are changing, the number of global trials is increasing, and study designs are more complex.”

A CMIC spokesperson told us that the company will provide feedback regarding Japanese CRO’s circumstances for developing technology standards. They added, “CMIC will join forces with global CRO partners to continue to develop open technology standards that makes it easier for sponsors and CROs to run collaborative clinical trials.”

The CRO specializes in using IT technology to create new methods for clinical trials and uses real-world data to create cost-efficient models. CMIC has worked as a solutions provider for clinical operations and implemented the use of virtual trials in the area.

CMIC provides end-to-end solutions from preclinical to clinical trials, drug development, and manufacturing, and from filing to post-market surveillance.

 

Related news

Show more

Related products

show more

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Related suppliers

Follow us

Products

View more

Webinars